Nukkleus Inc. Files 8-K with Financials and Exhibits
Ticker: DFNSW · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1787518
Sentiment: neutral
Topics: financial-statements, exhibits, regulation-fd
Related Tickers: NUKK
TL;DR
NUKK filed an 8-K on 10/22/24 with financials and exhibits.
AI Summary
Nukkleus Inc. filed an 8-K on October 22, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Brilliant Acquisition Corp., is incorporated in Delaware and its fiscal year ends on September 30th. The filing provides information regarding its common stock and warrants.
Why It Matters
This filing provides updated financial information and exhibits for Nukkleus Inc., which is important for investors to assess the company's current financial health and operational status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial statements and exhibits, with no immediate indication of significant new risks.
Key Numbers
- 0930 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Nukkleus Inc. (company) — Registrant
- Brilliant Acquisition Corp. (company) — Former company name
- October 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39341 (commission_file_number) — SEC File Number
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.
What is the significance of the 'Regulation FD Disclosure' item?
A Regulation FD Disclosure item means the company is disclosing material non-public information to the public, often to ensure fair disclosure.
When did Nukkleus Inc. change its name from Brilliant Acquisition Corp.?
The filing states the date of name change was September 9, 2019.
What is the par value per share for Nukkleus Inc.'s common stock?
The par value per share for Nukkleus Inc.'s common stock is $0.0001.
What is the exercise price for the warrants issued by Nukkleus Inc.?
The warrants are exercisable for one share of common stock at $11.50 per share.
Filing Stats: 423 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-10-22 08:00:17
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NUKK The Nasdaq
- $11.50 — sable for one Share of Common Stock for $11.50 per share NUKKW The Nasdaq Stock Ma
Filing Documents
- ea0217906-8k_nukkleus.htm (8-K) — 37KB
- ea0217906ex99-1_nukkleus.htm (EX-99.1) — 14KB
- 0001213900-24-089430.txt ( ) — 269KB
- nukk-20241022.xsd (EX-101.SCH) — 4KB
- nukk-20241022_def.xml (EX-101.DEF) — 26KB
- nukk-20241022_lab.xml (EX-101.LAB) — 36KB
- nukk-20241022_pre.xml (EX-101.PRE) — 25KB
- ea0217906-8k_nukkleus_htm.xml (XML) — 6KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 NUKKLEUS INC. (Exact name of registrant as specified in its charter) Delaware 001-39341 38-3912845 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification Number) 525 Washington Blvd. Jersey City , New Jersey 07310 (Address of principal executive offices) 212 - 791-4663 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share NUKK The Nasdaq Stock Market LLC Warrants, each warrant exercisable for one Share of Common Stock for $11.50 per share NUKKW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On October 22, 2024, the Company issued a press release titled, "Nukkleus Announces Reverse Stock Split". A copy of the press release is attached hereto as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated October 22, 2024 104 Cover Page Interactive Data File (embedded within the InLine XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUKKLEUS INC. Date: October 22, 2024 By: /s/ Menachem Shalom Name: Menachem Shalom Title: Chief Executive Officer 2